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C a v 1.2 has a key role in cardiac muscle excitation-contraction coupling 1 and in determining the plateau phase of the action potential. 2 In pathological conditions, Ca V 1.2 currents can trigger electric instability, early after-depolarizations, arrhythmias, and sudden death frequently in the setting of adrenergic stimulation or decreased repolarizing currents. 3, 4 Increased Ca V 1.2 activity can also lead to Ca 2+ overload, which in turn can result in arrhythmogenic-delayed after-depolarizations.
Although heterologous expression of Ca V 1.2 channels has proven useful for investigating biophysical properties, it has not been as successful for exploring physiological modulation, especially as related to cardiomyocytes. Knock-in mice are considered the gold standard, but they are time-consuming and expensive to generate, and a phenotype of heart failure or death during the perinatal period may preclude studies at later stages of development. 14, 30 Although adenoviruses have been used to express Ca V 1.2 subunits in cardiomyocytes, creation of adenoviruses encoding α 1C is difficult because of the α 1C insert size and the cardiomyocytes need to be cultured for extended period, potentially inducing dedifferentiation. Because overexpression of α 1C or β subunits reduces the hormonal regulation of the channel 27, [31] [32] [33] and can induce cardiac dysfunction or apoptosis, [34] [35] [36] [37] it is also important to limit the amount of overexpression. To circumvent these problems, which have limited progress in the field, we have developed an approach of using a doxycycline-inducible, tissue-specific, transgenic mouse-expressing FLAG-epitope-tagged, DHP-resistant α 1C . The approach preserves hormonal regulation of Ca v 1.2 by limiting Ca V 1.2 overexpression.
Prominent roles for proteolytic cleavage of α 1C , at residue Ala 1800 , and PKA phosphorylation of Ser 1700 , in the C-terminus of α 1C (Figure 1A) , in mediating β-adrenergic-induced enhancement of cardiac Ca V 1.2 current have been proposed, on the basis of heterologous expression of Ca V 1.2 subunits. 8, 14, 15 In the absence of proteolytic cleavage at Ala 1800 , PKA is unable to phosphorylate Ser 1700 and upregulate the activity of heterologously expressed Ca V 1.2. 15 Ala-substitution of the neighboring Thr 1704 , a residue that may be phosphorylated by casein kinase II, reduced heterologously expressed basal Ca V 1.2 channel activity in unstimulated tsA-201 cells, and when combined with Ala-substitution of Ser 1700 , more effectively reduced forskolininduced stimulation of Ca V 1.2, compared with Ala-substitution of Ser 1700 alone. These concepts have not been tested in cardiomyocytes. We tested these predictions in native cardiomyocytes by creating a transgenic mouse expressing 3 mutations within α 1C (S1700A, T1704A, and Δ 1798 NNAN 1801 ).
Methods

Reagents
Nisoldipine (Santa Cruz) was dissolved daily in 30-mmol/L ethanol and was protected from light. All other chemicals were acquired from Sigma.
Animals
The pseudowild-type (pWT) α 1C and ΔNNAN-S1700A-T1704A constructs were generated by fusing the rabbit CACNA1C cDNA (accession X15539) to the modified murine α-myosin heavy chain (MHC), tetracycline-inducible promoter (responder line) vector (gift of Drs Robbins and Molkentin). 38, 39 A 3X FLAG-epitope was ligated in-frame to the N-terminus of α 1C . The α 1C subunit was engineered to be DHP-insensitive with the substitutions T1066Y and Q1070M. 40, 41 Transgenic founder mice were identified with genomic DNA using polymerase chain reactions. These mice were bred with cardiac specific (αMHC) doxycycline-regulated codon-optimized reverse transcriptional transactivator (rtTA) mice (obtained via Mutant Mouse Regional Resource Center and Dr Tom Cooper, Baylor College of Medicine) 42 to generate double transgenic mice. We selected founder lines that did not express the transgenic α 1C in the absence of doxycycline. 
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Immunoblots and Immunofluorescence
For immunoblots, cardiomyocytes were isolated 43 from 8-to 12-week-old nontransgenic and doxycycline-fed transgenic mice. Cardiomyocytes were homogenized in a 1% Triton X-100 buffer containing (in mmol/L): 50 Tris-HCl (pH7.4) 150 NaCl, 10 ethylenediaminetetraacetic acid, 10 ethylene glycol tetraacetic acid, and protease inhibitors. The lysates were incubated on ice for 30 minutes, centrifuged at 14K rpm at 4 o C for 10 minutes, and supernatants were collected. Proteins were size-fractionated on SDS-PAGE, transferred to nitrocellulose membranes, and probed with anti-FLAG (Sigma) or anti-α 1C antibodies. Detection was performed with a CCD camera (Carestream Imaging). Image quantification was performed using ImageQuant software. For immunofluorescence, isolated cardiomyocytes were fixed for 15 minutes in 4% paraformaldehyde. Indirect immunofluorescence was performed using a 1:200 rabbit anti-FLAG antibody (Sigma) and 1:200 fluorescein isothiocyanate-labeled goat-anti-rabbit antibody (Sigma). Images were acquired using a confocal microscope.
Cellular Electrophysiology
Lipofectamine 2000 (Life Technologies) was used to transfect tsA-201 cells, which were plated onto 12-mm glass coverslips. The experiments were performed 24 to 48 hours after transfection. The isolated cardiomyocytes 43 and tsA-201 cells were superfused with (in mmol/L) 140 tetraethylammonium-Cl, 1.8 CaCl 2 , 1 MgCl 2 , 10 glucose, and ten 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, adjusted to pH 7.4 with CsOH. All experiments were performed at room temperature, 22±1 o C. Membrane currents were measured by the wholecell patch-clamp method using a MultiClamp 700B amplifier (Axon Instruments). The pipette solution contained (in mmol/L) 135 CsCI, 10 ethylene glycol tetraacetic acid, 1 MgCl 2 , 2 Mg-ATP, 2.0 CaCl 2 , and ten 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, adjusted to pH 7.2 with CsOH. Pipette series resistances were usually <1 MΩ after 60% compensation. Leak currents and capacitance transients were subtracted by a P/4 protocol. To measure Ca 2+ peak currents, the cell membrane potential was held at −70 mV and stepped to +10 mV for 350 ms every 5 to 10 seconds. To evaluate the current-voltage relationship for Ca 2+ currents, the same protocol was repeated with steps between −50 mV and +50 mV in 10 mV increments.
Fractional Shortening
Freshly isolated myocytes were perfused with a Tyrode's solution containing 1.8-mmol/L CaCl 2 . Myocytes were field-stimulated at 1-Hz. In 1 series of experiments, nisoldipine (300 nmol/L) was superfused in the absence and presence of isoproterenol (200 nmol/L). In the second series of experiments, cardiomyocytes were placed in a Tyrode's solution containing 300-nmol/L nisoldipine. A Tyrode's solution containing 300-nmol/L nisoldipine and 200-nmol/L isoproterenol was superfused. Fractional shortening of sarcomere length was measured using the SarcLen module of Ionoptix.
Statistical Analysis
Results are presented as mean±SEM. For multiple group comparisons, a 1-way ANOVA followed by Tukey, Sidek, or Dunnett post hoc tests were performed. For comparisons between 2 groups, an unpaired Student t test was used. Statistical analyses were performed using Prism 6 (Graphpad Software). Differences were considered statistically significant at values of P<0.05
Results
Generation of Inducible, Cardiac-Specific α 1C Transgenic Mice
We deleted the highly conserved 1798 NNAN 1801 motif in α 1C ( Figure 1B ) and coexpressed the cDNA with the β 2 subunit in tsA-201 cells. Deletion of this highly conserved region did not affect expression, trafficking to the surface, or the basal electrophysiological characteristics of Ca V 1.2 ( Figure 1C-1D ). Because proteolytic cleavage of α 1C does not occur when wild-type (WT) α 1C is expressed heterologously, the effect of deletion of the putative cleavage site on proteolysis of α 1C could not be assessed using this approach ( Figure 1C ). We generated transgenic mice with inducible cardiomyocyte-specific expression of a N-terminal 3X FLAG-epitopetagged, DHP-resistant α 1C , designated pWT α 1C using a bitransgenic tetracycline-regulated system that permits robust expression only when both transgenes and doxycycline are present ( Figure 2A ). The α 1C subunit was engineered to be relatively DHP-insensitive with the substitutions T1066Y and Q1070M. 40, 41 The IC 50 for nisoldipine block of heterologously expressed WT α 1C was 12 nmol/L, whereas the IC 50 for pWT α 1C was 650 nmol/L (Online Figure I ). We selected a concentration of 300 nmol/L nisoldipine as optimal for further experiments because nisoldipine (300 nmol/L) blocked >98% of heterologously expressed WT Ca V 1.2 current in tsA-201 cells, but only blocked 34.6±2.5% of DHP-insensitive α 1C (Online Figure I ).
Seven pWT α 1C founder transgenic lines were originally generated. Two founder lines were lost because of mortality, possibly because of high levels of doxycycline-independent α 1C expression. Four founder lines, when crossed with αMHC-rtTA mice, demonstrated doxycycline-induced expression of α 1C , assessed by anti-FLAG antibody immunoblots ( Figure 2B , upper; Online Figure II). One transgenic founder line, after crossing with αMHC-rtTA mice, did not demonstrate doxycycline-induced α 1C expression. Of 59 pWT α 1C bitransgenic mice treated with doxycycline, 18 mice (31%) died within 5 days of doxycycline administration possibly because of high levels of doxycycline-dependent α 1C expression.
We also generated a transgenic mouse line expressing 3 mutations within α 1C , Ala-substitutions of Ser 1700 (S1700A) and Thr 1704 (T1704A), and deletion of the 1798 NNAN 1801 motif (ΔNNAN), in the background of a N-terminal 3X FLAGepitope tag and DHP-resistance (ΔNNAN-S1700A-T1704A). Six ΔNNAN-S1700-T1704A mutant transgenic founder lines were originally generated. Three founders, when crossed with αMHC-rtTA, demonstrated doxycycline-induced α 1C expression ( Figure 2B , upper; Online Figure II ). The other 3 founders, after crossing with αMHC-rtTA mice, had either no or low levels of doxycycline-induced expression. Of the 35 ΔNNAN-S1700A-T1704A mutant mice treated with doxycycline, 9 mice (26%) died within 5 days, possibly because of high levels of α 1C expression. The 41-pWT α 1C transgenic mice and the 26 ΔNNAN-S1700A-T1704A mutant transgenic mice form the basis of this study.
Confirming the expression of transgene, immunofluorescence staining of fixed cardiomyocytes from pWT and ΔNNAN-S1700A-T1704A mutant transgenic mice with an anti-FLAG antibody showed a membrane distribution of expressed α 1C subunits consistent with t-tubular localization ( Figure 2D ). No staining was detected in cardiomyocytes when the anti-FLAG antibody was omitted. September 13, 2013
Cardiomyocyte contraction requires Ca 2+ influx via Ca V 1.2, which triggers sarcoplasmic reticulum Ca 2+ release. Superfusion of nisoldipine inhibited the contraction of nontransgenic cardiomyocytes to electric field stimulation at 1-Hz ( Figure 2E ). In cardiomyocytes isolated from pWT α 1C transgenic mice, the effect of nisoldipine was greatly diminished ( Figure 2F ). This indicates that the transgenic channels are correctly localized in the t-tubule and can initiate excitationcontraction coupling.
Proteolytic Processing of Transgenic Channels
Expression of cDNA encoding FLAG-tagged α 1C in tsA-201 cells migrated as full-length α 1C without evidence of proteolytic processing, detected by immunoblots using anti-FLAG and anti-α 1C antibodies ( Figures 1C and 2B ). In cardiomyocytes isolated from nontransgenic mice (C57Bl/6), native α 1C was detected as a full-length ≈240-kDa band and a cleaved ≈210-kDa band, using an anti-α 1C antibody created against an internal epitope within the intracellular loop of domains II and III. Native α 1C in nontransgenic mice cannot be detected using an anti-FLAG antibody ( Figure 2B ). Both the pWT α 1C transgenic channels and the transgenic channels with a deletion of 1798 NNAN 1801 were proteolytically cleaved, detected using the anti-FLAG antibody ( Figure 2B ; Online Figure  II ). The ratios of cleaved to full-length pWT and ΔNNAN transgenic α 1C were 62%±4% and 72%±5%, respectively, not significantly different than the 79%±5% cleavage of the native α 1C ( Figure 2C ). Because deletion of the putative proteolytic cleavage site had no effect on the ratio of truncated to full-length α 1C in cardiomyocytes, we can conclude that the NNAN motif and Ala 1800 are not required for post-translational cleavage of α 1C .
Functional, Inducible Expression of pWT and Mutant DHP-Insensitive Transgenic α 1C in Cardiomyocytes
We measured Ca V 1.2 currents in adult cardiomyocytes from nontransgenic and transgenic mice ( Figure 3A-3E ). The mean current density was significantly larger in the doxycycline-fed transgenic mice than in the nontransgenic mice (5.9±0.8 pA/pF [n=12] in nontransgenic cardiomyocytes; 12.9±0.9 pA/pF in pWT α 1C cardiomyocytes [n=43; P≤0.0001 compared with nontransgenic]; and 9.9±0.5 pA/ pF in ΔNNAN-S1700A-T1704A mutant cardiomyocytes [n=82; P<0.05 compared with nontransgenic]; Figure 3F ). Nisoldipine (300 nmol/L) inhibited 92.4%+1.6% of endogenous peak Ca 2+ current in cardiomyocytes isolated from nontransgenic mice (n=12), but 70%+3.6% of peak current in cardiomyocytes isolated from doxycycline-fed pWT α 1C transgenic mice (n=43; P≤0.001 compared with nontransgenic) and 70%+1.8% of peak current in the cardiomyocytes isolated from doxycycline-fed ΔNNAN-S1700A-T1704A Figure 2 . Inducible, cardiac-specific FLAG-tagged α 1C -expressing transgenic mice. A, Schematic representation of the binary transgene system. The αMHC-rtTA is the standard cardiac-specific reverse tetracyclinecontrolled transactivator system. The αMHC MOD construct is a modified αMHC promoter containing the tet-operon (tetO) for regulated expression of FLAGtagged, DHP-resistant (DHP*) α 1C . B, Anti-FLAG antibody (upper) and anti-α 1C antibody (lower) immunoblots showing FLAG-epitope-tagged α 1C expression in tsA-201 cells transfected with FLAGtagged α 1C and expression in isolated cardiomyocytes from either pWT α 1C or ΔNNAN-S1700A-T1704A transgenic mice. C, Bar graph of densitometries of cleaved α 1C band divided by truncated+full-length α 1C bands. n=4 NTG mice; n=10 pWT α 1C mice; n=6 ΔNNAN-S1700A-T1704A mice. P=not significant by ANOVA. D, Immunostaining of pWT α 1C and ΔNNAN-S1700A-1704A cardiomyocytes with or without (negative control) anti-FLAG antibody (Ab) and fluorescein isothiocyanate-conjugated secondary antibody, and nuclear labeling with Hoechst stain. Images obtained with confocal microscope at ×40 magnification. E and F, Time course of changes in sarcomere length after superfusion of nisoldipine (300 nmol/L) containing solution. Cardiomyocytes were field-stimulated at 1-Hz. αMHC indicates α-myosin heavy chain; DHP, dihydropyridine; NTG, nontransgenic; pWT, pseudowild-type; rtTA, reverse transcriptional transactivator; and TG, transgenic.
mutant transgenic mice (n=82; P≤0.001 compared with nontransgenic). In other words, ≈30% of the peak current in the cardiomyocytes isolated from doxycycline-treated transgenic mice was insensitive to nisoldipine ( Figure 3G ). The voltage dependence of Ca V 1.2 activation for endogenous, transgenic pWT and ΔNNAN-S1700A-T1704A α 1C were equivalent ( Figure 3D and 3E) , implying that at least under basal conditions, the modulation of transgenic Ca V 1.2 channels by accessory proteins was similar to endogenous Ca V 1.2 channels.
Adrenergic Modulation of Ca V 1.2 in WT α 1C Transgenic Mice
In cardiomyocytes isolated from nontransgenic mice, we measured the effects of the β-adrenergic agonist, isoproterenol, in the presence of nisoldipine. Isoproterenol (200 nmol/L) increased the small amount of residual Ca V 1.2 current by a mean of 2.5±0.2-fold ( Figure 4A and 4F ). Other groups have shown a similar response to isoproterenol stimulation in adult murine cardiomyocytes, with a range of 1.6-to 2.8-fold increase in basal currents. 25, 28, 32, 44, 45 In the cardiomyocytes isolated from pWT α 1C transgenic mice, isoproterenol increased the nisoldipine-insensitive peak current by a mean of 1.7±0.1-fold ( Figure 4B , 4D, and 4F; P≤0.01 compared with nontransgenic). In cardiomyocytes with a basal current density before nisoldipine of <10 pA/pF, which is similar to the basal current density of cardiomyocytes from nontransgenic mice, isoproterenol increased Ca V 1.2 currents by 2.1±0.3-fold ( Figure 5A ; P=not significant compared with nontransgenic). In cardiomyocytes with peak Ca V 1.2 currents >15 pA/pF, in contrast, isoproterenol increased Ca V 1.2 currents by only 1.4±0.1-fold ( Figure 5A ; P<0.05). Across the broad range of basal current densities, the effect of isoproterenol on the nisoldipine-resistant current was inversely correlated with the basal total Ca V 1.2 current ( Figure 5B ). The diminished adrenergic modulation of the transgenic pWT Ca V 1.2 current compared with endogenous Ca V 1.2 is likely because of the increased basal Ca V 1.2 current density in the transgenic cardiomyocytes. Cardiomyocytes may have a limited number of permissive sites on the membrane where PKA-mediated upregulation of Ca V 1.2 current can occur and channels in excess of this limited number may be less responsive to β-adrenergic stimulation, thereby diluting the overall fold-increase in Ca V 1.2 currents. 27
Phosphorylation of Ser 1700 and Thr 1704 Are Not Required for Isoproterenol-and Forskolin-Induced Stimulation of Ca V 1.2 Currents
Freshly isolated cardiomyocytes were isolated from doxycycline-treated ΔNNAN-S1700A-T1704A transgenic mice. In the presence of nisoldipine, isoproterenol increased peak Ca V 1.2 current by a mean of 1.7±0.1-fold, identical to the isoproterenol-induced augmentation of current in pWT α 1C transgenic cardiomyocytes (P=not significant; pWT α 1C versus ΔNNAN-S1700A-T1704A; Figure 4C , 4E, and 4F). In the presence Figure 3 . Dihydropyridine-resistant currents in transgenic mice. A through C, Exemplar whole-cell Ca V 1.2 currents recorded from pulses from −70 mV to +10 mV before (black traces) and 3 minutes after (red traces) of 300 nmol/L nisoldipine. D and E, Current-voltage relationships of pWT α 1C (D) and ΔNNAN-S1700A-T1704A Ca V 1.2 (E) acquired before (black traces) and 3 minutes after superfusion of 300-nmol/L nisoldipine. Insets: series of whole-cell Ca V 1.2 currents recorded from a series of pulses between −40 mV and +50 mV from a holding potential of −70 mV in the absence of nisoldipine (black traces) and 3 minutes after 300 nmol/L nisoldipine (red traces). F and G, Combined bar graph and column scatter plot for total peak current density (pA/pF) and peak DHP-resistant current density (pA/pF). Bar graphs are mean+SEM. ***P<0.0001; ***P<0.001; *P<0.05 by 1-way ANOVA and Sidak post hoc test. DHP indicates dihydropyridine; NTG, nontransgenic; pWT, pseudowild-type; and TG, transgenic. September 13, 2013 of nisoldipine, forskolin increased peak Ca V 1.2 current by a mean of 1.9±0.1-fold increase in cardiomyocytes isolated from the ΔNNAN-S1700A-T1704A mice, nearly identical to the 1.8±0.1-fold increase in pWT α 1C cardiomyocytes (Online Figure III) .
Similar to the pWT α 1C transgenic mice, the magnitude of isoproterenol-induced increase in nisoldipine-insensitive Ca 2+ current was inversely correlated with the basal total Ca V 1.2 current ( Figure 5C and 5D) . The slopes and intercepts of the 2 linear regression lines describing the relationship of total basal current density and response to isoproterenol of pWT and ΔNNAN-S1700A-T1704A α 1C were not statistically different ( Figure 5D ). In cardiomyocytes with a total basal Ca V 1.2 current density <10 pA/pF, isoproterenol caused a 1.8±0.1-fold increase in Ca V 1.2 current (P=not significant compared with pWT transgenic α 1C ). In cardiomyocytes with basal Ca V 1.2 current density >15 pA/pF, isoproterenol increased Ca V 1.2 currents by 1.3±0.1-fold (P=not significant compared with pWT α 1C ). Stratifying the magnitude of the isoproterenol effect by the fraction of nisoldipine-resistant current also demonstrated that the increase in Ca 2+ current was equivalent for WT α 1C and ΔNNAN-S1700A-T1704A α 1C (Figure 5E and 5F) . Thus, phosphorylation of Ser 1700 or Thr 1704 is not required for isoproterenol-or forskolin-induced modulation of Ca V 1.2 current.
Isoproterenol-Induced Modulation of Fractional Shortening Is Preserved in Cardiomyocytes Isolated From ΔNNAN-S1700A-T1704A Mutant Mice
We incubated cardiomyocytes for at least 2 minutes in the superfusion solution containing 300-nmol/L nisoldipine, to ensure that all cardiomyocytes were exposed to nisoldipine. In nontransgenic cardiomyocytes, >95% of the cardiomyocytes failed to contract to electric field stimulation at 1-Hz, and in the remaining cardiomyocytes, contraction was reduced by 80% (Online Figure IVA and IVB) . Isoproterenol increased the fractional shortening of the myocytes by 1.5fold, both in the absence and presence of 300 nmol/L nisoldipine (Online Figure IVA and IVB) . The cardiomyocytes isolated from both FLAG-tagged pWT and FLAG-tagged ΔNNAN-S1700A-T1704A, DHP-resistant transgenic mice were relatively resistant to the effects of nisoldipine (Online Figure IVA and IVC) . More than 90% of cardiomyocytes demonstrated sustained contraction to electric field stimulation at 1-Hz. Isoproterenol increased the fractional shortening of myocytes, in the presence of nisoldipine, in both pWT and ΔNNAN-S1700A-T1704A transgenic lines by 1.6-and 1.7-fold, respectively (Online Figure IVA and IVC) . Thus, phosphorylation of either Ser 1700 or Thr 1704 is not required for β-adrenergic modulation of excitation-contraction coupling in murine cardiomyocytes. (n=4) and ΔNNAN-S1700A-T1704A mice (n=8). Mean±SEM. Insets: series of whole-cell Ca V 1.2 currents recorded from a series of pulses between −50 mV and +50 mV from a holding potential of −70 mV in the presence of nisoldipine, before (red trace) and 3 minutes after (blue trace) 200 nmol/L isoproterenol. F, Combined bar and column scatter plot depicting the foldincrease in peak current caused by isoproterenol. Bar graphs are mean+SEM. **P<0.01 by ANOVA and Tukey post hoc test. n=6 nontransgenic cardiomyocytes; n=24 pWT α 1C ; n=56 ΔNNAN-S1700A-T1704A cardiomyocytes. NTG indicates nontransgenic; and pWT, pseudowild-type.
Discussion
In this study, we have developed an approach to probe molecular aspects efficiently and reliably of Ca V 1.2 regulation within the context of freshly isolated cardiomyocytes, approximating the ease and power of a heterologous expression system. In prior studies, overexpression of α 1C or β subunits markedly reduced the β-adrenergic regulation of the channel and induced cardiac dysfunction or apoptosis. 31, 32, [34] [35] [36] To circumvent these problems, we created inducible, tissue-specific, transgenic mice-expressing, DHP-resistant, FLAG-epitope-tagged α 1C . This approach preserves hormonal regulation of Ca V 1.2 by limiting its overexpression. The channels containing the transgenic α 1C are transported appropriately to the dyad and can initiate excitation-contraction coupling.
Using this newly developed approach, we now show that β-adrenergic regulation of cardiac Ca V 1.2 channels is unaltered by Ala-substitution of Ser 1700 or Thr 1704 , indicating that these sites are dispensable for this purpose in adult cardiomyocytes. Ser 1700 was recently reported to be the functionally relevant PKA site in heterologously expressed Ca V 1.2. 15, 29 Phosphorylation of Thr 1704 , a consensus site for casein kinase II, increases the basal activity of heterologously expressed Ca V 1.2. 15 It may also play a role in adrenergic modulation of Ca V 1.2, because forskolin-induced stimulation of heterologously expressed Ca V 1.2 was more attenuated with the double mutant S1700A-T1704A than for S1700A alone. 15 Although Ser 1928 is PKA phosphorylated, 11, [16] [17] [18] [19] [20] [21] [22] [23] it is not required for β-adrenergic stimulation of Ca V 1.2, 24, 25 and forskolin-induced stimulation of the heterologously expressed triple mutant S1700A-T1704A-S1928A was not different than the double mutant S1700A-T1704A. 15 It is based on these experiments 15 that we chose the S1700A-T1704A mutations for testing in transgenic mice. We were unable to assess the role of Thr 1704 on basal activity in cardiomyocytes, however, because the basal activity of heterologously expressed Ca V 1.2 was determined by comparing the coupling efficiency of pore opening to gating charge movement. 15
β-Adrenergic Stimulation of Ca V 1.2 Currents Is Robust in Doxycycline-Regulated Transgenic Mice
The isoproterenol-induced increase in current in the cardiomyocytes from transgenic mice is similar to previously reported studies. Muth et al 32 reported that isoproterenol (100 nmol/L) induced a 1.7±0.2-fold increase in peak Ca 2+ current, but only a 1.2±0.1-fold increase in cardiomyocytes isolated from α 1C overexpressing transgenic mice. Brandmayr et al 28 reported that isoproterenol (100 nmol/L) increased peak current by 1.9±0.25-fold in WT mice and 1.8±0.25-fold in mice with a deletion of the βsubunit C-terminus at Pro 501 . Nichols et al 44 reported an approximate 2-fold increase in Ca V 1.2 currents by isoproterenol (100 nmol/L) in WT and AKAP5 knock-out mice. Figure 5 . Analysis of isoproterenol's effects on transgenic Ca 2+ currents. A and C, Bar graphs of isoproterenol-induced increase in nisoldipineresistant current binned by total basal current density before nisoldipine for pWT α 1C (A) and ΔNNAN-S1700A-T1704A transgenic mice (C). Mean±SEM. *P<0.05 by ANOVA and Tukey post hoc test. For pWT α 1C , n=9 cardiomyocytes for 1 to 10 pA/pF; n=9 cardiomyocytes for 10 to 15 pA/pF; n=8 cardiomyocytes for >15 pA/pF. For ΔNNAN-S1700A-T1704A, n=33 cardiomyocytes for 1 to 10 pA/pF; n=17 for 10 to 15 pA/pF; n=6 for >15 pA/pF. B and D, Graphs of isoproterenolinduced increase in nisoldipine-resistant current stratified by total basal current density before nisoldipine for pWT α 1C (B), and pWT α 1C and ΔNNAN-S1700A-T1704A transgenic mice (D). Lines fitted by linear regression. The differences between the slopes and intercepts of pWT α 1C and ΔNNAN-S1700A-T1704A are not significant. E, Bar graph of isoproterenol-induced increase in nisoldipine-resistant current binned by fraction of nisoldipine-resistant current for pWT α 1C and ΔNNAN-S1700A-T1704A mice. Mean±SEM. P=not significant. F, Graph of isoproterenol-induced increase in nisoldipine-resistant current stratified by fraction of nisoldipine-resistant current for pWT α 1C and ΔNNAN-S1700A-T1704A mice. The differences between the slopes and intercepts of pWT α 1C and ΔNNAN-S1700A-T1704A are not significant. pWT indicates pseudowild-type; and TG, transgenic. September 13, 2013
Wang et al 45 reported that isoproterenol increased Ca V 1.2 currents in WT mice by 1.6-fold, but isoproterenol did not increase the current amplitude in transgenic mice overexpressing the β 2a subunit. Thus, by limiting overexpression of α 1C and only inducing expression of α 1C for 1 to 5 days, we have developed a highly reliable system that can accurately and efficiently report the functional effects of mutations.
A New Approach to Study the Regulation of Ca V 1.2 in Cardiomyocytes
Although useful for investigating biophysical properties, heterologous expression systems have not been successful for exploring physiological modulation, especially as related to cardiomyocytes. 14, 27, 30, 46 Compared with creating a knock-in mouse, expressing transgenic DHP-resistant α 1C mutants in the heart is rapid and cost-effective, and multiple sites within α 1C can be mutated at 1 time, regardless of intron/exon boundaries. There are, however, drawbacks using the approach. Transgenic expression naturally increases the basal current density, potentially disrupting normal stoichiometry and regulation. In the case of β-adrenergic modulation of Ca V 1.2, the magnitude of β-adrenergic stimulation is reduced with increased basal current density. Reducing the dynamic range of modulation could theoretically minimize the effects of the mutations on β-adrenergic regulation of Ca V 1.2. Stratifying the magnitude of β-adrenergic-mediated upregulation of Ca V 1.2 current by total basal current density attenuates this confounding variable.
With or without stratification by basal current density, we found that acute β-adrenergic stimulation of Ca V 1.2 is not significantly altered by Ala-substitution of Ser 1700 , implying that phosphorylation of Ser 1700 is not the primary mechanism for β-adrenergic regulation of Ca V 1.2. Could phosphorylation of Ser 1700 play a small, secondary role in mediating β-adrenergic regulation of Ca V 1.2, especially under conditions of relatively low basal current density at which the effect of β-adrenergic stimulation is greatest? At low basal current density, the mean increase in current for cardiomyocytes isolated from pWT α 1C transgenic mice was 2.11±0.25-fold, whereas for cardiomyocytes from the ΔNNAN-S1700A-T1704A transgenic mice, the mean increase was 1.84±0.25-fold, a nonsignificant relative difference of 13%. In this low basal current density group, the current density of the cardiomyocytes from the ΔNNAN-S1700A-T1704A transgenic mice was slightly higher than pWT α 1C transgenic mice (6.5 pA/pF versus 5.5 pA/ pF), which may have contributed to the slightly lower increase β-adrenergic stimulation in the ΔNNAN-S1700A-T1704A transgenic mice.
Assuming 7% of endogenous current is not blocked by nisoldipine ( Figure 2 ) and 65% of DHP-insensitive transgenic channels are not blocked by nisoldipine (Online Figure I) , the maximal contamination of nisoldipine-resistant currents by endogenous channels would be ≈8% at 40% nisoldipine-resistant current to total current and ≈14% at 30% nisoldipine-resistant current to total current (See Online Methods). At 40% fractional nisoldipine resistance in the cardiomyocytes isolated from ΔNNAN-S1700A-T1704A mice, the effects of β-adrenergic stimulation are identical to cardiomyocytes isolated from pWT α 1C mice ( Figure 5E ). Taken together, these findings imply that phosphorylation of Ser 1700 and Thr 1704 cannot be the primary mechanism by which β-adrenergic agonists activate Ca V 1.2 in the adult cardiomyocytes.
Proteolytic Cleavage Does Not Require the Conserved Motif 1798 NNAN 1801
Because proteolytic cleavage cannot be reconstituted in heterologous expression, there is no effective way to study the process, other than in native tissues. Indirect evidence, consisting of mass spectrometric analysis of the skeletal muscle α 1S proteolytic peptides and sequence alignments of α 1S and α 1C , was used to identify Ala 1800 as the putative proteolytic site in α 1C . 8 Deletion of Ala 1800 and the immediately adjacent conserved residues did not alter the proteolytic cleavage of α 1C , suggesting that either Ala 1800 is not the site in cardiomyocytes or that there is redundancy. Within the region, there are other similar motifs including 1794 NANI 1797 , which would combine with Asn 1802 after 1798 NNAN 1801 is deleted to form a 1794 NANIN motif. Whether cleavage could occur at Ala 1795 in ΔNNAN transgenic mouse is a question for future study.
In summary, we have developed an approach to test informative mutants of Ca V 1.2 in cardiomyocytes using a transgenic mouse approach. By limiting overexpression of the Ca V 1.2 α 1C subunit, we can reliably assess sympathetic regulation of Ca V 1.2. These data demonstrate that phosphorylation of Ser 1700 and Thr 1704 are not the primary mechanisms mediating β-adrenergic modulation of both Ca 2+ current and excitation-contraction coupling in adult cardiomyocytes.
